A Phase 3, Randomized, Observer-blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine in Comparison with a Licensed Quadrivalent Influenza Vaccine, in Adults 50 to 64 Years of Age - Phase 3 Immunogenicity Study of aQIV in Adults 50 to 64 Years of Age
100 项与 Seqirus UK Ltd. 相关的临床结果
0 项与 Seqirus UK Ltd. 相关的专利(医药)
100 项与 Seqirus UK Ltd. 相关的药物交易
100 项与 Seqirus UK Ltd. 相关的转化医学